This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Imprimis (B)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717496-EEntrepreneurshipThis case is a supplement to Imprimis (Case A). It describes the company's decision to enter into the pharmaceutical compounding business in 2013-14. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients' eyes post-cataract surgery, with the aim of replacing a complex regimen of prescription eye drops. After a successful launch of the compounded medication, Imprimis ran into complica...Starting at €5.74
-
KiOR: Catalyzing Clean Energy
Nanda, Ramana; Stuart, TobyCase HBS-809092-EEntrepreneurshipBiofuels start-up KiOR was developing a proprietary technology that had the potential to dramatically impact the emerging renewable energy landscape: a process that converted cellulosic biomass into "bio-crude," a hydrocarbon mixture with properties to those of crude oil. KiOR had been operating as a virtual organization, but with venture financing in place, founder and chief technology officer Paul O'Connor and the KiOR board needed to decide wh...Starting at €8.20
-
Tennant Company
Stuart, Toby; Applegate, Lynda M.; Weber, JamesCase HBS-810040-EEntrepreneurshipTennant, a leading producer of floor cleaning equipment, must determine how to create, finance, structure, staff, govern, measure and manage a new venture for developing a fundamentally new product line. In 2005, Tennant Company had developed an innovative, environmentally friendly, cleaning technology that could potentially revolutionize cleaning. Historically, Tennant was a producer of floor and carpet washing machines for industrial and commer...Starting at €8.20
-
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
Stuart, Toby; Webber, JamesCase HBS-813029-EEntrepreneurshipDescribes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate?Starting at €8.20
-
Imprimis (D)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717498-EEntrepreneurshipThis case is a supplement to Imprimis (Case A), Imprimis (Case B), and Imprimis (Case C). It describes Imprimis's 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750/pill. Imprimis also created compounded alternatives to several other branded drugs, and made investments to increase its manufacturing capabilities. The company now ha...Starting at €5.74
-
Sirtris Pharmaceuticals: Living Healthier, Longer
Stuart, Toby; Kiron, DavidCase HBS-808112-EEntrepreneurshipDescribes a set of key strategic decisions facing the scientific founder and CEO of a promising, Early stage bio-pharmaceuticals company.l Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate?Starting at €8.20
-
GSK's Acquisition of Sirtris: Independence or Integration, Teaching Note
Stuart, TobyTeaching Note HBS-811012-EEntrepreneurshipTeaching Note for 809026.Starting at €0.00
-
Imprimis (A)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717426-EEntrepreneurshipThis case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The A case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in 2013. At the time, Imprimis was in the process of seeking FDA approval for a branded drug called Impracor. This process, already difficult, was further complicated by recent manufactur...Starting at €8.20
-
Imprimis (C)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717497-EEntrepreneurshipThis case is a supplement to Imprimis (Case A) and Imprimis (Case B). Set in 2015, it first describes Imprimis's decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the problem of high drug prices in the United States. Recent, drastic price hikes on pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO ...Starting at €5.74
-
GSK's Acquisition of Sirtris: Independence or Integration
Stuart, Toby; Weber, JamesCase HBS-809026-EEntrepreneurshipAn executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's Global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science. Slaoui must balance the need to recoup shareholder value after paying a two-times premium for Sirtris with his desire to retain Christoph Westphal, Sirtris's co-founder and CEO, and othe...Starting at €8.20